Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-27
2008-05-27
Weber, Jon P (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C424S184100, C424S236100, C424S247100, C530S350000
Reexamination Certificate
active
07378389
ABSTRACT:
The invention provides for the use of a presynaptic neurotoxin (for example a bacterial neurotoxin such as botulinum toxin A) for the manufacture of a medicament for the treatment of cerebral palsy in juvenile patients. The juvenile patients are preferably juveniles of up to 6 years in age.
REFERENCES:
patent: 2373454 (1945-04-01), Bumy et al.
patent: 2719102 (1955-09-01), Baldwin, Jr.
patent: 3132995 (1964-05-01), Berger et al.
patent: 4234566 (1980-11-01), Packman et al.
patent: 4713240 (1987-12-01), Wilkins et al.
patent: 4720494 (1988-01-01), Felger et al.
patent: 4832936 (1989-05-01), Holter et al.
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 4935969 (1990-06-01), Farnsworth
patent: 5053005 (1991-10-01), Borodic
patent: 5055291 (1991-10-01), Lam et al.
patent: 5055302 (1991-10-01), Laties et al.
patent: 5056291 (1991-10-01), Leung
patent: 5183462 (1993-02-01), Borodic
patent: 5298019 (1994-03-01), Borodic
patent: 5401243 (1995-03-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5512547 (1996-04-01), Johnson et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5696077 (1997-12-01), Johnson et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6290961 (2001-09-01), Aoki et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6319505 (2001-11-01), Aoki et al.
patent: 6333037 (2001-12-01), Aoki et al.
patent: 6372226 (2002-04-01), Aoki et al.
patent: 6395277 (2002-05-01), Graham
patent: 6448231 (2002-09-01), Graham
patent: 6500436 (2002-12-01), Donovan
patent: 6623742 (2003-09-01), Voet
patent: 6683049 (2004-01-01), Aoki et al.
patent: 6841156 (2005-01-01), Aoki et al.
patent: 6872397 (2005-03-01), Aoki et al.
patent: 6887476 (2005-05-01), Aoki et al.
patent: 6939852 (2005-09-01), Graham
patent: 6974578 (2005-12-01), Aoki et al.
patent: 6986983 (2006-01-01), Aoki et al.
patent: 2001/0018415 (2001-08-01), Aoki et al.
patent: 2002/0102275 (2002-08-01), Graham
patent: 2003/0118598 (2003-06-01), Hunt
patent: 2004/0014663 (2004-01-01), Aoki et al.
patent: 2004/0126396 (2004-07-01), Aoki et al.
patent: 2004/0126397 (2004-07-01), Aoki et al.
patent: 2004/0151740 (2004-08-01), Aoki et al.
patent: 2005/0084504 (2005-04-01), Aoki et al.
patent: 2005/0112146 (2005-05-01), Graham
patent: 2272697 (1994-05-01), None
patent: WO93/05800 (1993-04-01), None
patent: WO94/00081 (1994-01-01), None
patent: WO94/00481 (1994-01-01), None
patent: WO94/15629 (1994-07-01), None
patent: WO94/28922 (1994-12-01), None
patent: WO94/28923 (1994-12-01), None
patent: WO95/17904 (1995-07-01), None
patent: WO95/28171 (1995-10-01), None
patent: WO95/30431 (1995-11-01), None
Hatheway et al. Botulinum Neurotoxin and Tetanus Toxin, 1989, Academic Press, Inc., Lane L. Simpson, editor, Chapter 1, Bacterial Sources of Clostridial Neurotoxins, pp. 3-24.
Adenis et al., “Treatment of Facial Spasm with Botulinum A Toxin,”J. Fr. Ophthal., 1990, 13(5):259-264.
Ambache, “A Further Survey of the Action ofClostridium botulinumToxin Upon Different Types of Autonomic Nerve Fibre,”J. Physiol., 1951, 113:1-17.
Ambache, “The peripheral action ofCl. botulinum toxin,” J. Physiol., 1949, 108(2):127-141.
Anderson et al., “Botulinum Toxin Treatment of Spasmodic Torticollis,”J. of the Royal Soc. Of Med., 1992, 85:524-529.
“Athena files US and Canadian Investigational New Drugs,”Scrip, Jun. 5, 1992, No. 1724, p. 29.
“Athena Makes a Wise Move,”Med. Advertising News, Nov. 1992, p. 4.
“Athena Outline Business Strategy,”Marketletter, Oct. 5, 1992.
Balkan et al., “A five year analysis of botulinum toxin type A injections: some unusual features,”Annals of Ophthalmology, 1991, 23(9):236-333.
Blasl et al., “Botulinum Neurotoxin A Selectively Cleaves the Synaptic Protein SNAP-25,”Nature, 1993, 365:160-163.
Berardelli et al., “Botulinum Toxin Treatment in Patients with Focal Dystonia and Hemifacial Spasm. A multicenter study of the Italian Movement Disorder Group,”Neurol. Sci, 1993, 14:361-367.
Bergmann et al., “Selective Degeneration of Sudomotor Fibers in Ross Sydrome and Successful Treatment of Compensatory Hyperhidrosis with Botulinum Toxin,”Muscle&Nerve, 1998, 21(12):1790-1793.
Biglan, “Experience with Botulinum A toxin (Oculinum) in the treatment of strabismus,”Contemp. Opth. Forum,1987, 5(6): 230-240.
Blitzer et al., “Electromyographic Finding in Focal Laryngeal Dystonia (Spastic Dysphonia),”Ann. Otol. Rhino. Laryngol., 1985, 94:591-594.
Bodde et al., “Transdermal Peptide Delivery,”Biochem. Soc. Trans., 1989, 17(5): 943-945.
“BOTOX,” 2000, 9 pages [web site].
“Botulinum Toxin for the Treatment of Facial Lines and Wrinkles,” 2005, [www.shorelaser.com/BotoxA.html], pp. 1-7.
“Botulinum Toxin may be useful in a range of muscular disorders,”Int. Med. News, 1991, 15:24(16):36.
Boghen, “Effectiveness of Botulinum Toxin in the Treatment of Spasmodic Torticollis,”Eur. Neurol., 1993, 33:199-203.
Borodic et al., “Botulinum B Toxin as an Alternative to Botulinum A Toxin: A Histologic Study,”Ophthal. Plast. Reconstr. Surg., 1993, 9(3):182-190.
Borodic et al., “Clinical and scientific aspects of botulinum A toxin,”Ophthalm Clinics of N. America, 1991, 4(3):491-503.
Boroff et al., “Amino acid analysis of the isolated and purified components from crystalline toxin ofClostridium botulinumtype A,”Infect. Immun., 1970, 2(5):679-680.
Brin, “Interventional Neurology: Treatment of Neurological Conditions with Local Infection of Botulinum Toxin,”Arch. Neurobiol., 1991, 54(5):173-189.
Brin et al, “Assessment: The clinical usefulness of Botulinum toxin A in treating neurologic disorders,”Neurology, 1990, 40: 1332-1336.
Brin et al., “Localized Injections of Botulinum Toxin for the Treatment of Focal Dystonia and Hemifacial Spasm,”Advances in Neurology, 1988, 50:599-608.
Buckelew, “Fibromyalgia: a rehabilitation approach. A review.,”Am. J of Phy. Med.&Rehab., 1989, 68(1):37-42.
Callaway, “Botulinum Toxin Type B: Pharmacology and Biochemistry,”Clinics in Dermatology, 2004, 22:23-29.
“Cervial Dystonia” [www.fpnotebook.com/NEU151htm]; pp. 1-2 (retrieved Sep. 3, 2003).
Choi et al., “Transdermal delivery of bioactive peptides: the effect of n-decylmethyl sulfoxide, pH, and inhibitors on Enkephalin metabolism and transport,”Pharm. Res.,, 1990, 7(11): 1099-1106.
Cioffi et al., “Microvasculature of the Anterior Optic Nerve,”Surv. Of Ophthal., 1994, 38: S107-S116.
Cohen et al., “Treatment of Focal Dystonias of the Hand with Botulinum Toxin Injection”Neurology, 1987, 37:123-124.
Clark, “Cervical Dystonia Following Exposure to High-G Forces,”Aviat. Space Environ. Me.,1990, 61: 935-937.
Cosgrove et al., “Botulinum toxin A prevents the developments of contractures in the hereditary spastic mouse model,”Dev. Med. And Child Neurol., 1994, 36: 379-385.
Cosgrove et al., “Botulinum toxin in the management of lower limb in cerebral palsy,”Dev. Med. And Child Neurol., 1994, 36: 386-396.
Das et al., “Effect of treatment with Botulinum toxin on spasticity,”Postgraduate Medical Journal, 1989, 65:208-210.
Dasgupta et al., “Purification ofClostridium botulinumtype A toxin Biochimica,”Biochim. Biophys. Acta., 1970, 214(2):343-349.
Dasgupta et al., “Role of a protease in natural activation ofClostridium botulinumneurotoxin,”Infect. Immun., 1972, 6(4):587-590.
Dasgupta et al., “Separation of toxin and Hemagglutinin from crystalline toxin ofClostridium botulinumtype A by anion exchange chromatography and determination of their dimensions by gel filtration,”J. Biol. Chem., 1969, 243(5):1065-1072.
Dasgupta, “The Structure of Botulinum Neurotoxin,”Botulinum Neurotoxin and Tetanus Toxin, 1989, pp. 53
Allergan Inc.
Donovan Stephen
Mohamed Abdel A
Weber Jon P
LandOfFree
Botulinum toxin neurotoxic component for treating juvenile... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum toxin neurotoxic component for treating juvenile..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum toxin neurotoxic component for treating juvenile... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2810581